Trametinib (trade name Mekinist & Meqsel both by Novartis ) is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity.It inhibits MEK1 and MEK2.
Are you looking for or in search of FDA approved “Trametinib tablets in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for melanoma. Need Access of “Trametinib tablets” for oral use for oral use, get in touch with our healthcare professional.
Trametinib dimethyl sulfoxide is approved to be used alone or with dabrafenib to treat patients whose cancer has a certain mutation in the BRAF gene, including:
- Anaplastic thyroid cancer that is locally advanced or has spread to other parts of the body and cannot be treated with local therapy. It is used with dabrafenib.
- Non-small cell lung cancer that has metastasized. It is used with dabrafenib.
- Solid tumors.
In May 2013, trametinib was approved as a single-agent by the Food and Drug Administration for the treatment of patients with V600E mutated metastatic melanoma. On January 8, 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma. On May 1, 2018, the FDA approved the combination dabrafenib/trametinib as an adjuvant treatment for BRAF V600E-mutated, stage III melanoma after surgical resection based on the results of the COMBI-AD phase 3 study, making it the first oral chemotherapy regimen that prevents cancer relapse for node positive, BRAF-mutated melanoma.